Customer Education

T Cell Webinar

 


 What Does it Cover?

Innate immune cells play a critical role in cell-mediated immunity and have the potential to serve as cell-based therapies to treat a broad spectrum of immune diseases such as cancer and autoimmune disorders. Modified immune cells, such as genetically engineered CAR-T cells, have proven to be critical in developing new cell-based therapies for these diseases. However, immune cell biology creates challenges during the gene-editing process that lead to hyper-regulated RNA and DNA sensing pathways and enhanced cell death upon introduction of exogenous ribonucleotides.

Further, engineering in primary immune cells is often restricted due to their limited expansion capacity. Genetic engineering in immune cells has traditionally relied on random integration of gene-editing components using viral delivery systems. In contrast, genome editing mediated by nucleases, such as CRISPR/Cas9-single guide RNPs, provide a platform for precision editing, and alleviate the potential side effects caused by randomly integrated viral DNA. While RNP gene editing in immune cells is just beginning to be considered by the immune-therapeutics field, our recent advances demonstrate that this approach can be used to create targeted modifications in two key cell types, the macrophage and the CD8+ primary T-cell. In an effort to circumvent challenges with the finite lifespan of primary T-cells, we targeted genes to edit that rendered this cell type “pseudo-immortalized”, thus allowing additional passages for further downstream genome editing and propagation.

In addition, we demonstrated that precision editing can be used to introduce disease relevant SNPs into the macrophage genome, which resist introduction of exogenous ribonucleotides due to the induction of apoptotic pathways. Advances such as these overcome many of the obstacles currently faced with immune cell editing and offer improved gene stability and expression in immune cells and, in doing so, will transform the Immuno-Oncology and Gene Therapy fields.

 

 What Will You Learn?

  • Methods for precision genome editing in macrophage and primary T cells
  • Cell line engineering workflow for immune cells

 Who Should Watch?

Researchers in the T-Cell, adaptive immunotherapy, and immuno-oncology fields

For more information about our cell design capabilities, please visit our Cell Design Studio

 

Speaker Bio
Laura Daley, PhD
Senior R&D Scientist, Cell Design Studio
Laura received her Ph.D. in Pharmacology and Physiology from the Saint Louis University School of Medicine in Saint Louis, MO, where she studied the transcriptional regulation of the retinoblastoma protein (RB) and its effects on E2F responsive genes as a function of cell cycle regulation. Following completion of her Ph.D., she joined the Department of Pediatrics at Stanford University School of Medicine as a postdoctoral fellow. Here, she investigated the role of RB and its family members, p107 and p130, in iPSC reprogramming and cellular differentiation. Laura then transitioned into industry, where she worked for two major industry leaders before joining us in 2010. She continues to play a fundamental role in immune cell gene editing, as a means to develop applications to advance the Immuno-Oncology and Gene Therapy fields.